Brain metastases in sarcoma patients: Incidence and outcome.

Hoiczyk, Mathias; Herbrik, Michael; Grabellus, Florian; Podleska, Lars Erik; Pöttgen, Christoph; Schwindenhammer, Benjamin; Bekas, Vassilis; Schüler, Martin; Bauer, Sebastian

doi:10.1200/jco.2014.32.15_suppl.10591

Cited by 11 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ASPS is a rare histology, characterised by a specific molecular change [t(X;17)(p11;q25) translocation, resulting in an ASPL-TFE3 gene fusion] [21], and is known to have an indolent clinical course in the non-metastatic stage, however characterized by late metastases with a 5-year OS of 20% at the metastatic stage [22,23]. ASPS feature a well-established preponderance for BMs, with a reported incidence of approximately 20-35% [22,[24][25][26][27][28]], compared to < 1-8% of sarcoma patients developing BMs overall [3,29,30]. Our study featured a median OS for the ASPS cohort (n = 14) of 17.33 months, indicating that a relatively long survival is retained event in the presence of BMs, consistent with previous sporadic reports [27].…”

Section: Discussionmentioning

confidence: 99%

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

Patrikidou

Chaigneau²,

Isambert

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: Brain metastases from sarcomatous lesions pose a management challenge owing to their rarity and the histopathological heterogeneity. Prognostic indices such as the Graded Prognostic Assessment (GPA) index have been developed for several primary tumour types presenting with brain metastases (e.g. lung, breast, melanoma), tailored to the specifics of different primary histologies and molecular profiles. Thus far, a prognostic index to direct treatment decisions is lacking for adult sarcoma patients with brain metastases. Methods: We performed a multicentre analysis of a national group of expert sarcoma tertiary centres (French Sarcoma Group, GSF-GETO) with the participation of one Canadian and one Swiss centre. The study cohort included adult patients with a diagnosis of a bone or soft tissue sarcoma presenting parenchymal or meningeal brain metastases, managed between January 1992 and March 2012. We assessed the validity of the original GPA index in this patient population and developed a disease-specific Sarcoma-GPA index. Results: The original GPA index is not prognostic for sarcoma brain metastasis patients. We have developed a dedicated Sarcoma-GPA index that identifies a subgroup of patients with particularly favourable prognosis based on histology, number of brain lesions and performance status. Conclusions: The Sarcoma-GPA index provides a novel tool for sarcoma oncologists to guide clinical decisionmaking and outcomes research.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

Patrikidou

Chaigneau²,

Isambert

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Patients with cancer will develop brain metastases (BM) with an incidence between 10% and 30% . The incidence of brain and meningeal metastasis in bone and soft tissue sarcomas (STS) is much lower, with estimates of 1%–8% . Published data are derived from small retrospective case series, often in the pediatric population.…”

Section: Introductionmentioning

confidence: 99%

“…Depending on their anatomic location, size, and number, neurosurgical resection is reported to be the cornerstone of the management of sarcoma BM . Radiation therapy has been used with little success.…”

Section: Introductionmentioning

confidence: 99%

Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)

et al. 2018

View full text Add to dashboard Cite

The incidence of brain and meningeal metastasis in bone and soft tissue sarcomas is estimated between 1% and 8%. Published data are derived from small retrospective case series, often in the pediatric population. A prognostic index is important to guide both clinical decision-making and outcomes research, but one such is lacking for adult sarcoma patients with brain metastases. The current study describes brain metastasis in a large cohort of sarcoma patients. This study, conducted within the French Sarcoma Group, describes the natural history of sarcoma brain metastasis and enables the proposal of strategic recommendations for subsequent clinical trials and for the management of such patients.

show abstract

“…Sarcomas are heterogeneous neoplasms and have much less potential for intracranial metastasis than epithelial tumors (2). The most frequent metastatic sites for sarcoma are lung, bone and liver (3). The reported incidence of sarcoma brain metastases ranges from 1-7% in adults (1, [3][4][5][6], and from 4.3.-8% in children (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

“…The most frequent metastatic sites for sarcoma are lung, bone and liver (3). The reported incidence of sarcoma brain metastases ranges from 1-7% in adults (1, [3][4][5][6], and from 4.3.-8% in children (7)(8)(9). Sarcoma types known to metastasize to the brain include Ewing sarcoma, Osteosaroma, leiomyosarcoma, rhabdomyosarcoma, alveolar soft part sarcoma and pleomorphic undifferentiated sarcoma (1,3-9).…”

Section: Introductionmentioning

confidence: 99%

Biology and treatment of metastasis of sarcoma to the brain

et al. 2016

View full text Add to dashboard Cite

Sarcomas are rare tumors with devastating clinical consequences, often affecting children as well as adults. Brain metastasis in sarcoma is frequently preceded by lung metastasis. Common offenders include Ewing sarcoma, osteosarcoma and leiomyosarcoma. Although our understanding of sarcoma metastasis remains limited, several cellular factors and signaling pathways appear to play regulatory roles and/or exhibit prognostic values in sarcoma metastasis. In addition, MicroRNAs have been shown to have either positive or negative impact on sarcoma biology and metastasis. Sarcoma is considered one of the classic radio- and chemo-resistant brain metastasis, hence the use of multiple modalities in order to improve the therapeutic ratio and overcome the inherent resistance. Treatment modalities include surgical resection, chemotherapy, gamma knife radiosurgery and/or fractionated whole-brain radiotherapy. The efficacy of chemotherapy is limited by the ability of the drug(s) to cross the blood-brain barrier (BBB), and the chemosensitivity of the tumor to the chemotherapeutic agent. In this review, we discuss the pathology, biology and therapy for sarcoma brain metastasis.

show abstract

Brain metastases in sarcoma patients: Incidence and outcome.

Cited by 11 publications

References 0 publications

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)

Biology and treatment of metastasis of sarcoma to the brain

Contact Info

Product

Resources

About